+1.7%
HUT vs MRNA
+945.0%
-943.3%
-63.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -23.2% | +13.1% | -36.3% | -24.0% |
| 7D | -29.5% | +20.6% | -50.2% | -30.5% |
| 30D | -45.2% | +27.1% | -72.3% | -46.0% |
| 3M | -51.6% | +353.4% | -405.0% | -59.7% |
| 6M | -37.3% | +446.3% | -483.6% | -55.3% |
| YTD | +6.5% | +776.2% | -769.6% | -43.4% |
| 1Y | +1.7% | +987.9% | -986.2% | -54.5% |
| All | +1.7% | +945.0% | -943.3% | -54.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling